Search

Your search keyword '"Brownstone, Nicholas"' showing total 471 results
Start Over Author "Brownstone, Nicholas"
471 results on '"Brownstone, Nicholas"'

151. Abstract 107

Author

Zhou, Anna T., primary, Rifkin, William, additional, More, Haresh, additional, Srivastava, Nikita, additional, Junejo, Muhammad H., additional, Kadle, Rohini L., additional, Kim, Camille, additional, Sartor, Rita A., additional, Brownstone, Nicholas D., additional, Montclare, Jin K., additional, Saadeh, Pierre B., additional, Rabbani, Piul S., additional, and Ceradini, Daniel J., additional

Published
2015
Full Text
View/download PDF

154. Alopecia's Impact on Mental Health.

Author

Brownstone, Nicholas

Subjects
MENTAL depression risk factors, BALDNESS, ALOPECIA areata, EMBARRASSMENT, PHOBIAS, MENTAL health, SOCIAL stigma, ATTITUDES toward illness, EXPERIENCE, PATIENTS' attitudes, MENTAL depression, ANXIETY, DISEASE risk factors, DISEASE complications
Abstract

The article discusses research on the psychological impact on patients with hair loss, as well as the importance of recognizing this condition and providing proper resources such as counseling or therapy. Topics include comments from Dr. John Koo, a board-certified in psychiatry and dermatology, on alopecia; description made by patients with alopecia areata (AA) on the initial diagnosis of alopecia; and research on the reciprocal relationship between mental health and alopecia.

Published
2023

155. Why is pimozide uniquely useful for the treatment of delusional patients in dermatology?

Author

Brownstone, Nicholas and Koo, John

Subjects
*DERMATOLOGY, *TOURETTE syndrome
Abstract

Even if the patient happens to develop TD, it is good for dermatologists to be aware that valbenazine and deutetrabenazine were approved for treatment of TD in 2017. Again, we commend the authors on discussing this important topic but would like to offer this pearl with the goal of making the dermatologist more comfortable and successful with the pharmacological treatment of delusional patients. [Extracted from the article]

Published
2022
Full Text
View/download PDF

156. 2023 Drug Pipeline.

Author

Brownstone, Nicholas

Subjects
BIOTHERAPY, THERAPEUTIC use of monoclonal antibodies, DRUG approval, PSORIASIS, BALDNESS, DERMATOLOGY, INVESTIGATIONAL drugs, ADALIMUMAB, EPIDERMOLYSIS bullosa
Abstract

In the article, the author discusses the possible drugs that could be approved for dermatologic therapy and pharmacology in 2023. Also cited are the various skin pathologies like infectious, neoplastic, and autoimmune, their treatments like monoclonal antibodies, steroids, and chemotherapeutic agents, and some dermatology drugs for approval like Pfizer's ritlecitinib for treating alopecia areata (AA).

Published
2023

157. Update on New Laser Treatments for Acne: Newly approved laser treatments can be an effective option for the treatment of this common skin disorder.

Author

Brownstone, Nicholas

Subjects
SEBACEOUS gland diseases, ROSACEA, SEBORRHEIC dermatitis, LASER therapy, MEDICAL care costs, DRUG resistance, BIOFILMS, PATIENT compliance, PATIENT safety, KERATINOCYTES
Abstract

The article presents update on laser treatments that can be an effective option for the treatment of acne, a disorder of the pilosebaceous unit that is characterized initially by comedones, which can progress to papules, pustules, nodules, and even abscesses. Topics discussed include pathophysiology of acne, description on AviClear laser, which targets sebaceous glands, and information on sebum-specific wavelengths for treatment of acne.

Published
2022

158. When to Progress to Systemic Therapy.

Author

BROWNSTONE, NICHOLAS

Subjects
ATOPIC dermatitis treatment, DERMATOLOGISTS, TREATMENT effectiveness, INTERPERSONAL relations, DECISION making in clinical medicine, PSYCHOTHERAPY
Abstract

The article discusses highlights of a presentation delivered by dermatology professor Eric Simpson at Maui Derm NP+PA Summer 2022 focused on systematic treatment options for atopic dermatitis (AD). Topics included guidance on the use of the Atopic Dermatitis Control Tool (ADCT), biologics targeting type 2 inflammation such as dupilumab and tralokinumab and oral Janus Kinase (JAK) inhibitors for AD treatment and factors to consider when prescribing a systemic therapy for AD.

Published
2022

159. Explore New Tactics for Acne Scars.

Author

Brownstone, Nicholas

Subjects
THERAPEUTICS, DERMATOLOGISTS, ACNE, SCARS, SKIN care, RADIO frequency therapy, LASER therapy, DERMABRASION, QUALITY of life, MENTAL depression, CHEMICAL peel, COMBINED modality therapy
Abstract

The article discusses new solutions to acne scars as of June 2022. Topics covered include the use of energy-based solutions like laser therapy and radiofrequency (RF) devices, and of non-energy-based modalities like chemical peels and surgical based treatments, matching of modality to the patient's needs and scar type, and boosting efficacy by combining procedures to achieve an additive effect. Also noted are the roles of pre- and postoperative skin care in achieving optimal results.

Published
2022

160. Update on the Genetics of Vitiligo.

Author

Brownstone, Nicholas

Subjects
DRUG approval, MENTAL health, RISK assessment, QUALITY of life, VITILIGO, DISEASE risk factors
Abstract

The author discusses a review article which offered an update on research into the genetic susceptibility of vitiligo. Topics include the risk of vitiligo attributed to genetic factors, candidate genes for vitiligo, and correlation between certain HLA types and specific subtypes of vitiligo in the Brazilian population according to research on the genetics of vitiligo.

Published
2023

161. The Psychosocial Impact of Vitiligo.

Author

Brownstone, Nicholas

Subjects
WELL-being, PIGMENTATION disorders, SELF-perception, MENTAL health, AUTOIMMUNE diseases, SOCIAL stigma, ATTITUDES toward illness, HYPOPIGMENTATION, QUALITY of life, MENTAL depression, ANXIETY, VITILIGO
Abstract

The article discusses the psychosocial effects of the pigmentary disorder called vitiligo, particularly on the quality of life (QOL) and social wellbeing of patients. According to studies, vitiligo is a barrier to marriage in some Middle Eastern countries, the comorbidities of the disease like depression, and the development of the Vitiligo-Specific-QOL instrument to measure and assess vitiligo's impact on QOL.

Published
2023

162. Surgical Treatment of Vitiligo.

Author

Brownstone, Nicholas

Subjects
OPERATIVE surgery, VITILIGO, TRANSPLANTATION of organs, tissues, etc.
Abstract

The article discusses the systematic review on the effectiveness of surgical therapies to treat vitiligo that was published in the August 2022 issue of "Dermatologic Surgery." Among the treatments are suction blister epidermal grafting, punch grafting, and cellular grafting. Also cited is the approval by the U.S. Food and Drug Administration (FDA) of topical ruxolitinib as vitiligo treatment.

Published
2023

163. Vitiligo Treatment With Phototherapy.

Author

Brownstone, Nicholas

Subjects
PHOTOTHERAPY, PIGMENTATION disorders, TREATMENT effectiveness, VITILIGO
Abstract

The article reports on the effectiveness of phototherapy as a treatment for vitiligo, a chronic autoimmune disease that causes destruction of melanocytes. Other topics include the disadvantages and side effects of some topical immune-modulating medications like their high prices, and some phototherapies like the narrow-band ultraviolet B (NB-UVB) phototherapy.

Published
2023

166. Treatment of AD with Ruxolitinib

Author

Chung, Bo Young, Orcales, Faye, Ildardashty, Alexander, Bhutani, Tina, Liao, Wilson, Norman, Robert A., Series Editor, Brownstone, Nicholas, editor, Liao, Wilson, editor, and Bhutani, Tina, editor

Published
2024
Full Text
View/download PDF

167. AD, Environment, and Diet

Author

Davis, Mitchell, Bhutani, Tina, Liao, Wilson, Norman, Robert A., Series Editor, Brownstone, Nicholas, editor, Liao, Wilson, editor, and Bhutani, Tina, editor

Published
2024
Full Text
View/download PDF

171. Comorbidities of AD

Author

Tully, Janell, Butler, Daniel C., Norman, Robert A., Series Editor, Brownstone, Nicholas, editor, Liao, Wilson, editor, and Bhutani, Tina, editor

Published
2024
Full Text
View/download PDF

172. Atopic Dermatitis in Skin of Color

Author

Ohanenye, Chiamaka, Zakria, Danny, Golant, Alexandra K., Norman, Robert A., Series Editor, Brownstone, Nicholas, editor, Liao, Wilson, editor, and Bhutani, Tina, editor

Published
2024
Full Text
View/download PDF

174. Infection and AD Flares

Author

Kilimnik, Madeleine, Narla, Shanthi, Jones, Elizabeth, Norman, Robert A., Series Editor, Brownstone, Nicholas, editor, Liao, Wilson, editor, and Bhutani, Tina, editor

Published
2024
Full Text
View/download PDF

175. Treatment of AD with Abrocitinib

Author

Jin, Joy Q., Spencer, Riley K., Elhage, Kareem G., Davis, Mitchell S., Hakimi, Marwa, Liao, Wilson, Bhutani, Tina, Norman, Robert A., Series Editor, Brownstone, Nicholas, editor, Liao, Wilson, editor, and Bhutani, Tina, editor

Published
2024
Full Text
View/download PDF

176. Treatment of Pediatric AD

Author

Ahmad, Regina-Celeste, Norman, Robert A., Series Editor, Brownstone, Nicholas, editor, Liao, Wilson, editor, and Bhutani, Tina, editor

Published
2024
Full Text
View/download PDF

177. Treatment of AD with Tralokinumab

Author

Elhage, Kareem G., Spencer, Riley K., Jin, Joy Q., Davis, Mitchell S., Hakimi, Marwa, Bhutani, Tina, Liao, Wilson, Norman, Robert A., Series Editor, Brownstone, Nicholas, editor, Liao, Wilson, editor, and Bhutani, Tina, editor

Published
2024
Full Text
View/download PDF

178. Treatment of AD with Upadacitinib

Author

Spencer, Riley K., Jin, Joy Q., Elhage, Kareem G., Davis, Mitchell S., Hakimi, Marwa, Liao, Wilson, Bhutani, Tina, Norman, Robert A., Series Editor, Brownstone, Nicholas, editor, Liao, Wilson, editor, and Bhutani, Tina, editor

Published
2024
Full Text
View/download PDF

180. Treatment of AD with Dupilumab

Author

Collier, Michael Ryan, Smith, Brandon, Devjani, Shivali, Engel, Priya, Wu, Jashin J., Norman, Robert A., Series Editor, Brownstone, Nicholas, editor, Liao, Wilson, editor, and Bhutani, Tina, editor

Published
2024
Full Text
View/download PDF

182. Screening for Early-Stage Skin Cancer Fuels Debate.

Author

BROWNSTONE, NICHOLAS

Subjects
MELANOMA diagnosis, DEBATE, EARLY detection of cancer, TUMOR classification, SKIN tumors, ELECTRONIC health records
Abstract

The article features debates in the screening for early-stage skin cancer as of 2022. Topics covered include a study that linked primary care-based melanoma screening with increased detection of thin melanoma, the dependence of melanoma survival on tumor stage, and the case against screening which views it as one of overdiagnosis. Also noted is the case for screening which argues that physicians detect thinner melanomas than those found by patients.

Published
2022

183. Meeting the Challenges of Acne in Adults.

Author

Brownstone, Nicholas

Subjects
ACNE, ISOTRETINOIN, ADULTS
Abstract

The article discusses the need for new solutions for adult acne that affects skin health and quality of life as of June 2022. Topics covered include acne's response to firstline, moderate, and severe case treatments, and women's additional treatments with hormonal therapy like spironolactone and oral contraceptives that are not appropriate for men. Also noted are the topical medication clascoterone that blocks androgen-mediated sebum production, and oralisotretinoin for recalcitrant acne.

Published
2022

184. Combine and Conquer.

Author

Brownstone, Nicholas

Subjects
RETINOIDS, ACNE, COMBINATION drug therapy, CLINDAMYCIN, ANTI-infective agents, TREATMENT effectiveness, HYDROCARBONS, CARBOCYCLIC acids
Abstract

The article discusses new combination therapies to address the multifactorial pathophysiology of acne vulgaris as of June 2022. Topics covered include improved patient adherence with combination agents, the greater than expected improvement with the triple formulation of clindamycin phosphate, benzoylperoxide, and adapalene, and these ingredients' equal contribution to the efficacy. Also noted is the therapy's reduction of antibiotic resistance.

Published
2022

185. Study Invites Second Look at Carvedilol.

Author

BROWNSTONE, NICHOLAS

Subjects
BIOLOGICAL models, CLINICAL trials, ROSACEA, ERYTHEMA, CATHELICIDINS, INFLAMMATION, PROTEOLYTIC enzymes, ADRENERGIC beta blockers, CARVEDILOL, TREATMENT effectiveness, TOLL-like receptors, PHARMACODYNAMICS
Abstract

The article discusses research on the molecular mechanisms underlying the efficacy of carvedilol in rosacea treatment. Histopathologic and immunohistochemical research results presented reveal the effectiveness of carvedilol in alleviating skin inflammation by downregulating inflammatory cytokines, as well as in upregulating cathelicidin expression, reducing erythema and inhibiting microphage infiltration.

Published
2022

186. IL-17 Class of Biologic Agents in Psoriatic Disease

Author

Soung, Jennifer, Stetkevich, Samuel, Ishizuka, Momoko, Berth-Jones, John, Series Editor, Goh, Chee Leok, Series Editor, Maibach, Howard I., Series Editor, Brownstone, Nicholas, editor, Bhutani, Tina, editor, and Liao, Wilson, editor

Published
2022
Full Text
View/download PDF

187. Psoriasis Biologic Agents in Special Populations

Author

Thatiparthi, Akshitha, Martin, Amylee, Liu, Jeffrey, Han, George, Wu, Jashin J., Berth-Jones, John, Series Editor, Goh, Chee Leok, Series Editor, Maibach, Howard I., Series Editor, Brownstone, Nicholas, editor, Bhutani, Tina, editor, and Liao, Wilson, editor

Published
2022
Full Text
View/download PDF

188. Combination Therapy with Biologic Agents

Author

Pony, Kourtney, Nakamura, Mio, Berth-Jones, John, Series Editor, Goh, Chee Leok, Series Editor, Maibach, Howard I., Series Editor, Brownstone, Nicholas, editor, Bhutani, Tina, editor, and Liao, Wilson, editor

Published
2022
Full Text
View/download PDF

189. Comparing Biologic Agents in Treatment of Psoriasis

Author

Hakimi, Marwa, Mosca, Megan, Hadeler, Edward, Hong, Julie, Liao, Wilson, Berth-Jones, John, Series Editor, Goh, Chee Leok, Series Editor, Maibach, Howard I., Series Editor, Brownstone, Nicholas, editor, Bhutani, Tina, editor, and Liao, Wilson, editor

Published
2022
Full Text
View/download PDF

190. Special Site Psoriasis

Author

Hong, Julie, Mosca, Megan, Hadeler, Edward, Hakimi, Marwa, Liao, Wilson, Berth-Jones, John, Series Editor, Goh, Chee Leok, Series Editor, Maibach, Howard I., Series Editor, Brownstone, Nicholas, editor, Bhutani, Tina, editor, and Liao, Wilson, editor

Published
2022
Full Text
View/download PDF

195. Long-Term Registry Data for Psoriasis Biologics

Author

Cull, Deborah, Pena, Joseph, Balogh, Esther A., Purvis, Caitlin G., Feldman, Steven R., Berth-Jones, John, Series Editor, Goh, Chee Leok, Series Editor, Maibach, Howard I., Series Editor, Brownstone, Nicholas, editor, Bhutani, Tina, editor, and Liao, Wilson, editor

Published
2022
Full Text
View/download PDF

196. Adherence to Biologic Therapy for Psoriasis

Author

Sun, Qisi, Perche, Patrick O., Ranpariya, Varun K., Feldman, Steven R., Berth-Jones, John, Series Editor, Goh, Chee Leok, Series Editor, Maibach, Howard I., Series Editor, Brownstone, Nicholas, editor, Bhutani, Tina, editor, and Liao, Wilson, editor

Published
2022
Full Text
View/download PDF

197. Laboratory Monitoring: HIV, TB and Hepatitis

Author

O’Connell, Katie A., Mari, Alexandra, Van Voorhees, Abby S., Berth-Jones, John, Series Editor, Goh, Chee Leok, Series Editor, Maibach, Howard I., Series Editor, Brownstone, Nicholas, editor, Bhutani, Tina, editor, and Liao, Wilson, editor

Published
2022
Full Text
View/download PDF

198. Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group.

Author

Farberg, Aaron S., Marson, Justin W., Glazer, Alex, Litchman, Graham H., Svoboda, Ryan, Winkelmann, Richard R., Brownstone, Nicholas, and Rigel, Darrell S.

Subjects
*SKIN cancer, *GENE expression profiling, *SENTINEL lymph node biopsy, *SKIN tests, *CANCER prevention
Abstract

Background: Prognostic assessment of cutaneous melanoma relies on historical, clinicopathological, and phenotypic risk factors according to American Joint Committee on Cancer(AJCC) and National Comprehensive Cancer Network (NCCN) guidelines but may not account for a patient's individual additional genetic risk factors. Objective: To review the available literature regarding commercially available gene expression profile (GEP) tests and their use in the management of cutaneous melanoma. Methods: A literature search was conducted for original, English-language studies or meta-analyses published between 2010 and 2021 on commercially available GEP tests in cutaneous melanoma prognosis, clinical decision-making regarding sentinel lymph node biopsy, and real-world efficacy. After the literature review, the Skin Cancer Prevention Working Group, an expert panel of dermatologists with specialized training in melanoma and non-melanoma skin cancer diagnosis and management, utilized a modified Delphi technique to develop consensus statements regarding prognostic gene expression profile tests. Statements were only adopted with a supermajority vote of > 80%. Results: The initial search identified 1064 studies/meta-analyses that met the search criteria. Of these, we included 21 original articles and meta-analyses that studied the 31-GEP test (DecisionDx-Melanoma; Castle Biosciences, Inc.), five original articles that studied the 11-GEP test (Melagenix; NeraCare GmbH), and four original articles that studied the 8-GEP test with clinicopathological factors (Merlin; 8-GEP + CP; SkylineDx B.V.) in this review. Six statements received supermajority approval and were adopted by the panel. Conclusion: GEP tests provide additional, reproducible information for dermatologists to consider within the larger framework of the eighth edition of the AJCC and NCCN cutaneous melanoma guidelines when counseling regarding prognosis and when considering a sentinel lymph node biopsy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

199. Perspectives on the Future Development of Mobile Applications for Dermatology Clinical Research.

Author

Hadeler, Edward, Hong, Julie, Mosca, Megan, Hakimi, Marwa, Brownstone, Nicholas, Bhutani, Tina, and Liao, Wilson

Subjects
*MEDICAL research, *MOBILE apps, *DERMATOLOGISTS, *COVID-19 pandemic, *SOCIAL distancing, *PHYSICIANS
Abstract

The COVID-19 pandemic significantly impacted clinical research in dermatology and practices around the country transitioned to teledermatology amid physical distancing requirements. Despite their growing use in teledermatology and clinical care, dermatology applications have not been studied extensively in the research space. The use of mobile applications has the potential to improve the experience of study subjects and physicians and increase the pool of individuals willing to participate in research beyond the pandemic. We discuss the various pros and cons of mobile apps, as well as the necessary components they require to successfully conduct research. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

200. Psoriasis and Cardiometabolic Comorbidities: An Evaluation of the Impact of Systemic Treatments in Randomized Clinical Trials.

Author

Mosca, Megan, Hong, Julie, Hadeler, Edward, Hakimi, Marwa, Brownstone, Nicholas, Liao, Wilson, and Bhutani, Tina

Subjects
*CLINICAL trials, *CARDIOVASCULAR diseases, *ATHEROSCLEROSIS, *PSORIASIS, *PSORIATIC arthritis, *BIOLOGICALS, *METABOLIC syndrome
Abstract

The association between psoriasis, metabolic syndrome, and cardiovascular disease is well established. The shared pathways between psoriasis, metabolic syndrome, and atherosclerosis suggest that treatments targeting the inflammatory pathways of psoriasis may also be beneficial in the treatment of associated cardiometabolic comorbidities. This paper reviews the most recent data regarding the impact of systemic psoriasis treatments on comorbid cardiovascular and metabolic disease. Data from randomized clinical trials with systemic and biologic agents are presented. Overall, studies demonstrate beneficial effects on several cardiometabolic markers and risk factors in psoriasis patients; however, longer randomized controlled trials to characterize the direct benefit for cardiovascular outcomes are needed. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results